Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - EMMAUS LIFE SCIENCES, INC. | a17-1384_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 5, 2017
Emmaus Life Sciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware |
|
000-53072 |
|
41-2254389 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
|
of Incorporation) |
|
File Number) |
|
Identification No.) |
|
21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 |
|
(Address, including zip code, off principal executive offices) |
|
|
|
Registrant’s telephone number, including area code 310-214-0065 |
|
|
|
|
|
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
Exhibit 99.1 to this report sets forth certain data from Emmaus Life Sciences, Inc.’s (“we,” “us.” “our, “Emmaus” or the “company) completed Phase 3 study entitled “A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia,” which we may present from time to time at various investor and analyst meetings.
The information furnished under this Item 7.01 shall not be deemed filed with the U.S. Securities and Exchange commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained in Exhibit 99.1 shall not be incorporated by reference into any filing we make regardless of general incorporation language in the filing, unless expressly incorporated by reference in such filing
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Phase 3 Study Data |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Emmaus Life Sciences, Inc. | |
|
|
| |
|
|
|
|
|
Date: January 5, 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Yutaka Niihara |
|
|
Name: |
Yutaka Niihara, M.D., MPH |
|
|
Title: |
Chairman and Chief Executive Officer |